Skip to content

Use of tranexamic acid with oxytocin to reduce bleeding during emergency caesarean section

Comparison of the effects of combined tranexamic acid plus oxytocin versus oxytocin alone in reducing blood loss during emergency caesarean section. A Randomized Controlled Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202605886170737
Enrollment
156
Registered
2026-05-04
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Postpartum Haemorrhage

Interventions

Sponsors

seif
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Pregnant women aged 20 – 40 years, with parity (1–4), carrying a live singleton fetus at term (gestational age =37 weeks but <42 weeks), scheduled for primary emergency caesarean section under spinal anaesthesia at Asokoro District Hospital, Abuja, who provide written informed consent.

Exclusion criteria

Exclusion criteria: Women with multiple gestations, known coagulopathies or bleeding disorders, severe pre-eclampsia/eclampsia, placenta previa or accreta, history of thromboembolic events, known allergy to tranexamic acid, significant hepatic, cardiac or renal impairment, those undergoing general anaesthesia, or those who decline to give informed consent will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure will be the mean intraoperative blood loss (in millilitres) between the two groups.

Secondary

MeasureTime frame
The secondary outcome measures will include: The incidence of excessive blood loss, ( defined as estimated blood loss of =1000 mL intraoperatively); The mean change in haematocrit levels; The need for additional uterotonic agents or blood transfusion; and the occurrence of maternal adverse drug events, including nausea, vomiting, hypotension, and thromboembolic complications.

Countries

Nigeria

Contacts

Public ContactKWARI SHIKTIRA DANLADI

Consultant Obstetrician and Gynaecologist

Shiktira.Kwari@nileuniversity.edu.ng+2348023611010

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026